News Search Results

Displaying Results 301-325 of 4671 "biotechnology"

Aug 01, 2024, 14:00 ET WesternU selects Dr. John Tegzes as College of Veterinary Medicine Dean

Calif. and Lebanon, Ore., is an independent nonprofit health professions university, conferring degrees in biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, osteopathic medicine, pharmacy, physical therapy, physician

More news about: Western University of Health Sciences


Aug 01, 2024, 11:00 ET Gain.pro announces the launch of the "European PE Asset Handbook"

with high profitability and above-average buy-and-build activity. Other subsectors that jump out are Professional Services, Technical Services and Biotechnology.By region, France, Italy and CEE emerge as attractive regions for

More news about: Gain.pro


Aug 01, 2024, 11:00 ET Gain.pro announces the launch of the "European PE Asset Handbook"

with high profitability and above-average buy-and-build activity. Other subsectors that jump out are Professional Services, Technical Services and Biotechnology.By region, France, Italy and CEE emerge as attractive regions for

More news about: Gain.pro


Aug 01, 2024, 10:30 ET Single-Use Bioreactors Market worth $9.1 billion by 2029 driven by Rising Tech Innovations | MarketsandMarkets™

expirations of blockbuster drugs. End-User Segmentation: Pharmaceutical & Biotechnology Companies Dominate Based on end users, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs) & contract manufacturing organizations

More news about: MarketsandMarkets


Aug 01, 2024, 10:01 ET Non-Hodgkin's Lymphoma Therapeutics Market to Reach USD 18.6 Billion by 2034: Fuelled by New Drugs and Targeted Therapies | Latest Report by TMR

Market: Key Players The non-hodgkin's lymphoma therapeutics market is characterized by intense competition among pharmaceutical and biotechnology companies, driven by the demand for innovative and effective treatments. The following companies are well known participants in the non-hodgkin's

More news about: Transparency Market Research


Aug 01, 2024, 10:01 ET Pain Management Drugs Market to Reach $109.6 Billion, Globally, by 2033 at 4.2% CAGR: Allied Market Research

Drugs Market Worldwide In January 2024, Heron Therapeutics, Inc. a commercial-stage biotechnology company announced that the U.S. Food and Drug Administration has approved its supplemental New Drug Application for ZYNRELEF to expand the indication

More news about: Allied Market Research


Aug 01, 2024, 09:50 ET Hitachi High-Tech Acquires Majority Interest in Nabsys

Tokyo, Japan, is engaged in activities in a broad range of fields, including manufacture and sales of clinical analyzers, biotechnology products, radiation therapy systems, semiconductor manufacturing equipment, analytical instruments, and analysis equipment. Also, we provide high

More news about: Nabsys


Aug 01, 2024, 09:15 ET NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announces positive 12-month iron biomarker data from its Phase IIb study

More news about: NeuroSense


Aug 01, 2024, 09:06 ET Vanguard Announces Portfolio Manager Change to Health Care Fund

Throughout her tenure at Wellington, Ms. Hynes was a Global Industry Analyst covering the pharmaceutical and biotechnology sectors through 2013, became sole portfolio manager and leader of the Health Care Team in 2013, was elected one of three Managing Partners in 2014,

More news about: Vanguard


Aug 01, 2024, 09:01 ET New Survey Shows Strong Patient Support for Personalized Obesity Interventions

Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, today announces the results from a new U.S. weight loss survey from 475 patients

More news about: Phenomix Sciences


Aug 01, 2024, 08:00 ET Angel Yeast Brings Together Innovative Consortium to Build Industrial Park for Synthetic Biology Development

USD 70.05 million), a 20.8 percent year-on-year increase. PHA is a new biodegradable material to replace plastics. Hubei PHAngel Biotechnology, a joint venture by Angel Yeast and Beijing PhaBuilder, is building a PHA production line with production capacity

More news about: Angel Yeast


Aug 01, 2024, 08:00 ET Angel Yeast bringt innovatives Konsortium zum Aufbau eines Industrieparks für die Entwicklung der Synthetischen Biologie zusammen

Prozent gegenüber dem Vorjahr entspricht. PHA ist ein neues biologisch abbaubares Material, das Kunststoffe ersetzen soll. Hubei PHAngel Biotechnology, ein Joint Venture von Angel Yeast und Beijing PhaBuilder, baut in zwei Phasen mit einer Gesamtinvestition von 1,05

More news about: Angel Yeast


Aug 01, 2024, 08:00 ET Angel Yeast Brings Together Innovative Consortium to Build Industrial Park for Synthetic Biology Development

20.8 percent year-on-year increase. PHA is a new biodegradable material to replace plastics. Hubei PHAngel Biotechnology, a joint venture by Angel Yeast and Beijing PhaBuilder, is building a PHA production line with production capacity

More news about: Angel Yeast


Aug 01, 2024, 08:00 ET Angel Yeast reúne a un consorcio para construir un parque industrial para desarrollar biología sintética

dólares), un aumento interanual del 20,8 por ciento. PHA es un nuevo material biodegradable para reemplazar a los plásticos. Hubei PHAngel Biotechnology, una empresa conjunta de Angel Yeast y Beijing PhaBuilder, está construyendo una línea de producción de PHA con una

More news about: Angel Yeast


Aug 01, 2024, 08:00 ET Curis Provides Second Quarter 2024 Financial and Operating Update

Mass., Aug. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its financial and

More news about: Curis, Inc.


Aug 01, 2024, 07:03 ET REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202

required support for breathing, cardiomyopathy and premature death. ABOUT REGENXBIO Inc.REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development

More news about: REGENXBIO Inc.


Aug 01, 2024, 07:00 ET Jade Biosciences Launches with $80 Million to Develop Transformative Therapies for Autoimmune Diseases

Mass., Aug. 1, 2024 /PRNewswire/ -- Jade Biosciences, Inc. ("Jade"), a biotechnology company dedicated to developing best-in-class therapies for patients living with autoimmune diseases, today announced the closing of an $80

More news about: Jade Biosciences


Aug 01, 2024, 06:45 ET Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity

life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:

More news about: Eli Lilly and Company


Aug 01, 2024, 06:30 ET Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today

More news about: Immunic, Inc.


Aug 01, 2024, 06:03 ET Nucleic Acid Therapeutics Market to Reach USD 22.1 Billion by 2034, Advances in Genetic Research and Biotechnology Propel Growth: Transparency Market Research Inc.

Advances in genetic research and biotechnology are propelling the nucleic acid therapeutics market value. These medicines, which include antisense oligonucleotides (ASOs), RNA interference (RNAi),

More news about: Transparency Market Research


Aug 01, 2024, 06:00 ET Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools

efficiency and accelerate the entire drug development life cycle." About Rejuvenate BiomedRejuvenate Biomed is a clinical-stage biotechnology company developing therapeutics that target the root causes of age-related diseases. Utilizing two clinically validated proprietary drug discovery

More news about: SAS


Aug 01, 2024, 03:47 ET MGI Tech Partners with UNALM and Inca Tops to Enhance Alpaca Fiber and Strengthen Peru's Textile Industry

focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various

More news about: MGI TECH


Jul 31, 2024, 18:30 ET To Further Advance Gene Therapy Research, Industry Pioneer Jim Wilson is Forming Two Independent Companies Dedicated to Genetic Medicine

also been active in facilitating the clinical and commercial development of these new gene therapy platforms through the establishment of eight biotechnology companies. His research has been focused on rare inherited diseases, ranging from cystic fibrosis to dyslipidemias to a variety of neurologic disorders

More news about: GEMMA Biotherapeutics and Franklin Biolabs


Jul 31, 2024, 17:50 ET Laboratory Automation Systems Market size is set to grow by USD 2.01 billion from 2024-2028, Increasing demand for laboratory automation software services boost the market, Technavio

Europe3.3 Asia3.4 Rest of World (ROW)1.1 Pharmaceutical and biotechnology companies-  Pharmaceutical and biotechnology companies are increasingly utilizing laboratory automation systems for high-content screening (HCS) applications in their

More news about: Technavio


Jul 31, 2024, 17:30 ET Hot Plate Stirrer Market size is set to grow by USD 437.42 million from 2024-2028, Advancements in design and functioning of hot plate stirrers boost the market, Technavio

magnet or rotating magnetic field. These devices are essential in various industries and laboratories for applications such as chemical reactions, biotechnology, pharmaceuticals, and food processing. E-commerce platforms and industrial goods suppliers cater to the demand for hot plate stirrers. Laboratories

More news about: Technavio